Insmed (INSM) — Deep Dive Investment Analysis with Hostile Review

Disclaimer: These reports include AI-generated summaries, often explicitly arguing one side as strongly as possible (positive or negative) and should not be relied on. They're designed to test theses and foster polite debate and scrutiny, so please comment if you see an error!

Date: March 30, 2026
Stock Price: ~$145.69 | Market Cap: ~$31.3B | EV: ~$30.6B
FY2025 Revenue: $606.4M | FY2025 Net Loss: -$1,276.8M | Cash: ~$1.4B

Executive Summary

Insmed is a rare disease biopharmaceutical company that has just gone from a one-product NTM specialist to a two-product respiratory platform with potentially the biggest specialty respiratory launch in years. BRINSUPRI (brensocatib) — the first and only approved treatment for non-cystic fibrosis bronchiectasis — posted $144.6M in its first full quarter (Q4 2025), nearly 3x analyst expectations, and management has guided to $1.0B+ in 2026 revenue. Combined with ARIKAYCE ($434M in 2025, with a label expansion catalyst from positive ENCORE results), Insmed is guiding to ~$1.5B in total 2026 revenue — more than doubling YoY. Consensus expects first profitability in 2027.

The bull case is that BRINSUPRI is a multi-billion-dollar blockbuster (peak sales estimates: $5-6.6B) treating a massively under-diagnosed disease with no approved alternatives. The $31B market cap is pricing in significant execution, but if the launch trajectory holds, this is still early innings for a franchise that could generate $5B+ in peak annual sales.

The bear case is that a 20% exacerbation reduction in a 52-week trial, priced at $88,000/year (24x ICER's cost-effective threshold), with a mechanism that has already failed in one expansion indication (rhinosinusitis), does not justify a $31B market cap for a company that has never been profitable in its 38-year history and has tripled its share count over the past decade. ICER voted unanimously (11-0) that brensocatib represents "low" long-term value for money. The stock trades at 51x trailing P/S and 42x P/B.

My read: The launch data is genuinely impressive. $144.6M in a first full quarter is a top-decile specialty drug launch by any measure, and it suggests the disease burden is real and physicians are eager to prescribe. But the valuation gives you almost no margin of error. At ~18x 2026 guided revenue for a company still losing $1.3B annually, you need BRINSUPRI to not just succeed but to be one of the most successful specialty drug launches in history. The CEDAR (hidradenitis suppurativa) data in Q2 2026 is the next binary event — it will tell us whether brensocatib's mechanism extends beyond bronchiectasis or whether the BiRCh (rhinosinusitis) failure was a harbinger.

Section 1: The Business — What You're Actually Buying

Two Commercial Products

ARIKAYCE (amikacin liposome inhalation suspension)

• First and only FDA-approved therapy for MAC lung disease (the most common form of NTM)
• Approved September 2018 (US), October 2020 (EU), March 2021 (Japan)
• 2025 revenue: $433.8M (+19% YoY)
• Delivered via once-daily nebulization using the Lamira Nebulizer System
• ENCORE Phase 3b results (March 23, 2026): culture conversion 87.8% vs. 57.0% on placebo for newly diagnosed patients — sNDA filing planned H2 2026 to expand label to first-line treatment
• Label expansion would grow addressable market from ~30,000 (treatment-refractory) to 200,000+ patients

BRINSUPRI (brensocatib)

• First-in-class DPP1 inhibitor; first and only approved treatment for non-cystic fibrosis bronchiectasis (NCFB)
• FDA approved August 12, 2025; EU approved November 2025
• Once-daily oral tablet (10mg) — a major compliance advantage over injectable/infused competitors
• Q4 2025 revenue: $144.6M (first full quarter, ~3x analyst expectations)
• 2026 guidance: $1.0B+
• Peak sales estimates: $5B+ (Insmed), $6.6B (Mizuho), $6.3B (Visible Alpha consensus)
• Annual list price: $88,000 (before 25-35% expected discounts)

Pipeline

What concerns me: Brensocatib already failed in CRSsNP (rhinosinusitis) in December 2025. The BiRCh study showed no benefit at either dose (10mg or 40mg). This is the first indication that DPP1 inhibition does not universally translate across neutrophil-mediated diseases. The CEDAR HS study is therefore critical — it either validates or further undermines the platform thesis.

Section 2: The P&L — Scaling Revenue, Deepening Losses

Annual Financial Trajectory

Key observation: Revenue is scaling rapidly (+67% in 2025, guided to ~+140% in 2026), but losses widened to $1.28B because SG&A grew 52% and R&D grew 29% to support the BRINSUPRI launch and pipeline expansion. This is the classic "invest through the launch" phase. Consensus expects the loss to narrow dramatically in 2026 (-$2.93 EPS vs. -$6.42 in 2025) and for Insmed to reach first profitability in 2027 (consensus EPS +$0.48).

Quarterly Revenue Trajectory (BRINSUPRI Ramp)

The Q4 number is the bull case in a single data point. $144.6M in a first full quarter against consensus of $57.6M is a remarkable launch. For context, the first full quarter of Dupixent (arguably the most successful specialty drug launch of the 2010s) was ~$180M — and Dupixent launched into a much larger atopic dermatitis market.

Balance Sheet

The balance sheet is adequate but not comfortable. $1.4B cash with ~$790M annual burn gives ~21 months of runway — but BRINSUPRI revenue is ramping fast enough that the company should reach cash flow breakeven without another raise. The risk is that if the launch stalls or pipeline investments grow, another dilutive raise is possible.

Section 3: The Competitive Landscape — First-Mover but Not Alone Forever

BRINSUPRI in Bronchiectasis

BRINSUPRI is the only approved treatment for NCFB anywhere in the world. This is a disease that affects 300,000-500,000 adults in the US and ~2 million globally, with no prior disease-modifying therapy. The standard of care has been airway clearance, antibiotics for exacerbations, and macrolide suppression — none of which are approved for bronchiectasis specifically.

What I like here: First-and-only approval in a large, under-served disease with no prior standard of care. Oral, once-daily dosing is a massive advantage. The launch trajectory ($144.6M Q4 2025) validates both disease burden and physician demand.

What concerns me: The competitive moat is narrower than it appears.

Boehringer's BI 1291583 is the most direct threat: a same-mechanism DPP1 inhibitor with better in vitro potency and a potentially better safety profile. If BI's Phase 3 reads out positively (timeline TBD, likely 2028+), BRINSUPRI's monopoly position ends. The question is whether Insmed can build enough market share and prescriber habit in the 2-3 year window before competition arrives.

ARIKAYCE in NTM

ARIKAYCE remains the only approved therapy for MAC lung disease. The competitive pipeline includes Paratek's omadacycline (oral, Phase 2b for M. abscessus) and RedHill's RHB-204 (oral triple-combination, Phase 3 for MAC). Neither is likely to directly compete with ARIKAYCE's inhalation-based approach, but oral alternatives could capture patients who resist nebulizer treatment burden.

Section 4: Valuation — What You're Paying

Analyst Consensus (24 analysts)

Average Price Target: $198 (+36% upside)
Range: $115 (low) to $245 (high, HC Wainwright)

Recent upgrades: BofA to $213, Stifel to $208, Mizuho to $206, Leerink to $215.

What the Market Is Pricing In

At $31.3B market cap on $606M TTM revenue, the market is pricing in:

• BRINSUPRI reaching $3-5B+ in peak sales
• Successful ex-US launches (EU, Japan)
• ARIKAYCE label expansion to first-line treatment
• Pipeline delivering additional value (TPIP, CEDAR HS data)
• First profitability by 2027

If all of this happens, the current price may be fair or cheap. If BRINSUPRI launch velocity slows, if CEDAR fails (following BiRCh's failure), or if Boehringer's competitor advances faster than expected, the stock has significant downside from a ~$31B market cap for a company still losing $1.3B annually.

Section 5: Bull and Bear Cases

Bull Case

1. BRINSUPRI is a genuine blockbuster. $144.6M in Q4 2025 is a top-decile specialty launch. If the $1B+ 2026 guide is met and the trajectory continues, $3-5B+ peak sales is achievable. At 10x peak sales, that alone justifies the current market cap.

2. ARIKAYCE's ENCORE success expands TAM 7x. First-line label would grow the addressable population from 30,000 to 200,000+. At current pricing, this could add $1B+ to ARIKAYCE's peak revenue.

3. TPIP is a multi-billion-dollar pipeline asset. Phase 3 trials initiating in PAH and PH-ILD — markets worth $5B+. TPIP's once-daily dry powder inhaler could be superior to United Therapeutics' Tyvaso (which requires a nebulizer).

4. DPP1 platform optionality. CEDAR HS data (Q2 2026) could validate brensocatib in another large market. Success would dramatically expand the platform.

5. Acquisition premium. GSK, AstraZeneca, and Novartis have all been cited as potential acquirers. A premium deal could value Insmed at $200-250+/share.

Bear Case

1. 20% exacerbation reduction is modest. At $88,000/year — 24x ICER's cost-effective threshold — the value proposition is fragile. ICER voted unanimously (11-0) that brensocatib represents "low" long-term value for money.

2. The mechanism already failed in one indication. BiRCh (CRSsNP) showed no benefit at any dose. If CEDAR (HS) also fails, the platform thesis collapses and BRINSUPRI is a single-indication drug in a relatively niche respiratory disease.

3. No clinical benefit in the sickest patients. ICER found no therapeutic benefit in subgroups with FEV1 <50% or BSI score >=9 — the patients who need help most.

4. 38 years of losses. Insmed has never been profitable. The net loss widened from $482M (2022) to $1,277M (2025). Share count has tripled over the past decade. Even if 2027 brings profitability, the consensus EPS of $0.48 on a $146 stock is a 300x P/E.

5. Coordinated insider selling, zero purchases. 111 insider sales and 0 purchases in the past 6 months. CEO, CFO, COO, and CLO all selling. Insider ownership at 0.64%.

6. Boehringer's verducatib is a direct, potentially superior competitor. Same mechanism (DPP1 inhibition), better in vitro potency (IC50 0.7 nM vs. 4.0 nM), and lower adverse event incidence. If BI advances to Phase 3, BRINSUPRI's monopoly window closes.

7. Payer headwinds are real. BRINSUPRI is not covered by most Medicare Part D plans without exception processes. Prior authorization requires documented macrolide failure. Payer contracts are still being finalized, with higher rebates likely to compress realized pricing.

Hostile Review

This section stress-tests the bull case by cataloguing every weakness, omission, and over-optimistic framing.

1. The "Blockbuster" Narrative Is Built on a 20% Exacerbation Reduction

Let's be precise about what the ASPEN trial showed. Brensocatib reduced the annualized rate of pulmonary exacerbations from 1.29 (placebo) to 1.02 (10mg). That is a rate ratio of 0.79 — a 21% relative reduction. In absolute terms, it's the difference between ~1.3 exacerbations per year and ~1.0 exacerbation per year. Over 52 weeks, on average, a patient on brensocatib experiences roughly one-third fewer exacerbations than a patient on placebo.

This is statistically significant (p=0.004) but the clinical meaningfulness is debatable. There is no validated MCID (minimum clinically important difference) for exacerbation rate in bronchiectasis, which means the field has no consensus on what constitutes a "meaningful" reduction. ICER, the independent clinical and economic review body, gave brensocatib a rating of B+ — "moderate certainty of a small or substantial net health benefit." Note the word "small."

For $88,000/year (list price), you are paying $88,000 for approximately 0.27 fewer exacerbations per year. That is roughly $326,000 per exacerbation avoided. ICER's health-benefit price benchmark is $3,100-$3,700/year — Insmed is charging 24x what ICER considers cost-effective. The independent appraisal committee voted unanimously (11-0) that brensocatib represents "low" long-term value for money at current pricing.

2. The Sickest Patients Don't Benefit

This is buried in the ICER report and rarely discussed by bulls. In pre-specified subgroup analyses, brensocatib showed no therapeutic benefit in patients with the most severe symptoms and worst lung function (FEV1 <50% predicted, BSI score >=9). These are the patients with the greatest unmet need — and the ones for whom the drug doesn't appear to work.

The implication: brensocatib's benefit is concentrated in milder patients who may have lower exacerbation rates to begin with and less urgency for treatment. The drug works best in patients who need it least.

3. FEV1 Improvement Is Below Clinical Significance

The 25mg dose showed a 38 mL improvement in FEV1 vs. placebo. The widely accepted MCID for FEV1 in obstructive lung diseases is 100-140 mL. Brensocatib's FEV1 benefit is roughly one-quarter to one-third of what is considered clinically meaningful. The 10mg dose (the approved dose) showed an even smaller FEV1 effect. Quality of life (QOL-B) improvement on the 10mg dose was not statistically significant (95% CI crossed zero).

4. DPP1 Inhibition Has Already Failed in Its First Expansion

The December 2025 BiRCh trial in chronic rhinosinusitis without nasal polyps (CRSsNP) was a complete failure — no benefit at 10mg or 40mg on any primary or secondary endpoint. This was supposed to validate the DPP1 platform thesis: that inhibiting neutrophil serine proteases would be broadly effective across neutrophil-mediated inflammatory diseases.

It didn't. The program was discontinued immediately. If DPP1 inhibition doesn't work in rhinosinusitis — another neutrophil-driven mucosal inflammatory disease — why should we be confident it will work in hidradenitis suppurativa (the CEDAR trial, data Q2 2026), or RA/IBD (INS1033)?

The bull response is that bronchiectasis has a different neutrophilic pathophysiology. That may be true — but it means brensocatib is a bronchiectasis drug, not a "neutrophil platform." And a single-indication drug with a 20% exacerbation reduction is a very different investment thesis than a multi-indication platform targeting $5B+ in peak sales.

5. 38 Years of Losses and a Tripled Share Count

Insmed was founded in 1988. It has never reported an annual profit. Cumulative losses are in the billions. The share count has grown from ~60M in the mid-2010s to ~216M today — a 3.6x dilution. In 2025 alone, the company did a $650M equity raise at $96/share and redeemed $569.5M in convertible notes (conversion price $32.50/share, potentially adding 17.5M shares).

The FY2025 net loss was $1.277 billion — wider than 2024's $914M, which was wider than 2023's $750M. SG&A grew 52% YoY to $701M. R&D grew 29% to $771M. Even on $606M of revenue, the company burned $1.28B. This is not a company that has historically demonstrated operating leverage.

Consensus expects first profitability in 2027 with EPS of $0.48. On a $146 stock, that's a 300x P/E. If you assume $3.00 EPS by 2029 (optimistic), you're paying 49x three-year-forward earnings. For a company with no track record of profitability.

6. Insider Selling Is Relentless

In the past 6 months: 111 insider sales, 0 insider purchases. Every C-suite executive — CEO William Lewis, CFO Sara Bonstein, COO Roger Adsett, CLO Michael Smith — has sold shares in coordinated fashion. Insider ownership stands at 0.64%. Yes, these are pre-planned 10b5-1 sales. But the total absence of any insider buying, combined with 0.64% ownership, sends a clear signal: the people who know this company best are not putting their own money behind the bull case.

7. Boehringer Ingelheim Is Coming

BI 1291583 (verducatib) is a same-class DPP1 inhibitor with:

• 5.7x better in vitro potency (IC50 for NE: 0.7 nM vs. brensocatib's 4.0 nM)
• Lower adverse event incidence (RR 0.80 vs. brensocatib's 1.10 in a meta-analysis of DPP1 inhibitors)
• Positive Phase 2 AIRLEAF dose-response data
• The backing of Boehringer Ingelheim, a $25B+ revenue pharma company with massive respiratory commercial infrastructure

If BI advances verducatib into Phase 3 (likely 2027-2028) and achieves better efficacy or safety, BRINSUPRI's monopoly position erodes. In respiratory, payers and physicians are accustomed to switching when a better option arrives. Insmed has a 2-3 year window to entrench market share — and the payer access challenges (prior authorization, macrolide failure requirements, Medicare Part D non-coverage) are making that harder.

8. The $5B Peak Sales Number Requires Heroic Assumptions

Insmed's own estimate of >$5B peak annual sales for brensocatib assumes:

• Penetration into a large portion of the 300,000-500,000 US bronchiectasis population
• Successful EU and Japan launches at comparable pricing
• Label expansions into additional indications
• No meaningful competition
• Sustained pricing at ~$60,000-$88,000/year

Analyst Stifel estimates a more conservative ~$3.5B global peak. Even that requires diagnosing hundreds of thousands of patients who are currently undiagnosed (40-53% of bronchiectasis cases are idiopathic and many patients are misdiagnosed with COPD). Under-diagnosis is a double-edged sword: the patients exist, but finding them costs money and time. Every undiagnosed patient needs an HRCT scan, a specialist visit, and a willingness to start a $88K/year drug.

9. The Papillon-Lefevre Safety Shadow

DPP1 inhibition pharmacologically mimics aspects of Papillon-Lefevre syndrome (PLS), a rare genetic condition caused by complete loss of DPP1 function. PLS patients experience severe periodontitis leading to premature tooth loss, palmoplantar keratoderma (thickened skin on palms/soles), and increased susceptibility to pyogenic skin infections.

BRINSUPRI carries a boxed warning for hyperkeratosis and periodontal disease. In the ASPEN trial, hyperkeratosis occurred in ~3% of patients on the 25mg dose. These are chronic, potentially irreversible effects. The ASPEN trial was only 52 weeks — long-term data beyond one year does not exist. ICER flagged "significant uncertainties regarding long-term efficacy and safety."

A drug that works by partially mimicking a genetic disease associated with tooth loss deserves more scrutiny than the consensus "Strong Buy" rating suggests.

10. At $31B, Insmed Is Too Expensive to Acquire and Too Expensive to Own

At $31.3B market cap, an acquisition would cost $35-40B+ with a typical premium. Bears argue: if GSK, AstraZeneca, or Novartis wanted Insmed, they would have bought it when the stock was $25-50 (2023-early 2024). At current prices, the risk-reward for an acquirer is poor — you're paying full price for unproven peak revenue and absorbing a $1.3B annual loss.

And for public market investors: you're paying ~18x 2026 revenue for a company that won't be profitable until 2027, in a sector where United Therapeutics (multiple approved PAH drugs, 50% operating margins) trades at 5x revenue. The premium is justified only if every piece of the bull case — BRINSUPRI blockbuster, ARIKAYCE label expansion, TPIP success, additional indication wins — comes together. The probability of all of these happening is materially lower than the probability of any one of them failing.

Section 6: Key Upcoming Catalysts

Section 7: Stock Performance

Key moves:

• May 2024: Stock doubled on positive ASPEN Phase 3 results
• August 2025: Surged on FDA approval of BRINSUPRI
• December 17, 2025: Dropped ~17% in one day on BiRCh (CRSsNP) trial failure
• February 2026: Rose ~7% on BRINSUPRI Q4 sales beat and $1B+ 2026 guide
• March 23, 2026: Positive ENCORE results for ARIKAYCE first-line label expansion

Short interest: 16.47M shares short (10.19% of float). Days to cover: 7.7. Persistent but not extreme.

Key Data Sources

• Insmed Q4/FY2025 Earnings Release
• FDA BRINSUPRI Approval
• NEJM — ASPEN Phase 3 Results
• ICER Final Evidence Report on NCFB
• ENCORE Results (Insmed IR)
• BiRCh CRSsNP Failure — BioPharma Dive
• Fierce Pharma — Blowout Brinsupri Sales
• BI 1291583 vs. Brensocatib — Springer Nature
• DPP1 Inhibitors Meta-Analysis — PMC
• StockAnalysis — INSM Statistics
• StockAnalysis — INSM Forecast
• DrugPatentWatch — Arikayce Patent Expiration
• Insmed J.P. Morgan Conference Update (Jan 2026)
• DelveInsight — NCFB Market
• TipRanks — Insider Trading